Personalis Stock (NASDAQ:PSNL), Trade Ideas

Personalis

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

Cathie Wood

Equities

News

Specialty ETFs

Trading Ideas

ETFs

ARKK

ARKQ

ARKW

BLDE

DKNG

PSNL

TSLA

Tesla found favor with bullish fund manager Cathie Wood, as her firm lapped up Tesla shares following its 10% slide over three sessions.

Cathie Wood&#39;s Ark Laps Up $3.3M Worth Of Tesla As Stock Falls For 3rd Straight Session, Sheds Shares Of This Sports Betting Company

cathie-wood-bz-ark

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

ARKF

DDOG

PINS

TWLO

VERV

Cathie Wood&#39;s Ark Invest Buys More Shares Of This Meta Platforms Competitor

World Economic Forum - Annual Meeting of the New Champions in Dalian, People's Republic of China 2017

Markets

COIN

HOOD

KTOS

PATH

RBLX

TWST

Cathie Wood&#39;s Ark Continues Tesla Stock Buying Spree, Acquires Over $14M Worth Of Shares Amid Dip

Personalis Inc

Citigroup analyst Atif Malik maintains Silicon Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLAB#NASDAQ">SLAB</a>) with a Neutral and lowers the price target from $137 to $120.

Price Target

Analyst Ratings

SLAB

Citigroup Maintains Neutral on Silicon Laboratories, Lowers Price Target to $120

In a compelling showcase of how sports figures leverage their platforms beyond the field, former NFL athletes <a href="https://www.benzinga.com/general/sports/24/04/38358885/joique-bell-to-discuss-journey-from-rookie-to-prominent-nfl-running-back-at-benzinga-draft-event">Joique Bell</a> and<a href="https://www.benzinga.com/markets/cannabis/24/03/37797148/former-nfl-legends-bring-top-cannabis-strains-to-boston-with-launch-of-primitiv"> Rob Sims</a> shared their philanthropic journeys today (April 25) during the <a href="https://www.youtube.com/watch?v=93htkUYdGNc">Benzinga Sports Business Titans Draft</a> event in Detroit. 
The panel, adjacent to the NFL Draft at Campus Martius, highlighted the transformative impact athletes can have in their communities post-retirement.
<h1 class="wp-block-heading">Athletes Turned Philanthropists</h1>
Moderated by Rachel Decker, president of Detroit Philanthropy, the conversation delved into the personal motivations behind the athletes&#8217; commitments to giving back. 
Bell, a Michigan native and former Detroit Lion, emphasized the influence of his upbringing on his charitable efforts. 
&#8220;Growing up, being involved in community service was ingrained in me by my parents,&#8221; Bell said. He discussed his focus on literacy and education through his foundation, which aims to improve reading levels among students within a short period significantly.
Sims, who transitioned from the gridiron to various business and charitable endeavors, highlighted his strategic approach to philanthropy. 
&#8220;It&#8217;s about making an impact with the resources we have, ensuring our efforts genuinely help those in need,&#8221; Sims stated. His involvement with local organizations such as Detroit PAL and the Children&#8217;s Center demonstrates his commitment to youth and community health.
<h1 class="wp-block-heading">Impact And Influence&nbsp;</h1>
The discussion also covered the athletes&#8217; strategies for selecting and managing philanthropic engagements. 
Both Bell and Sims stressed the importance of aligning with causes that reflect their values and where they can make a meaningful difference. Bell shared his rigorous approach to vetting organizations before partnering with them, ensuring alignment with his goals to support community development.
<h1 class="wp-block-heading">Advice For The Next Generation&nbsp;</h1>
As the event drew the attention of young athletes and aspiring philanthropists, Bell and Sims offered advice on starting and running charitable foundations. 
&#8220;Understand the work that goes into managing a foundation; it&#8217;s akin to running a business,&#8221; Sims advised. Bell echoed this sentiment, emphasizing the importance of commitment and genuine passion for the cause.
<h1 class="wp-block-heading">Legacy Beyond The Field&nbsp;</h1>
Reflecting on their legacies, both athletes expressed a desire to be remembered for their contributions off the field as much as their achievements on it. 
&#8220;It&#8217;s not just about the sports; it&#8217;s about using our platform to make a lasting impact,&#8221; said Bell.
Photo by Dustin Blitchok.

Sports

Events

Game Changers: Ex-NFL Players Talk Philanthropy For Today And Next-Gen At Benzinga Titans Draft Event

Citigroup analyst Ronald Josey maintains Lithia Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAD#NYSE">LAD</a>) with a Neutral and lowers the price target from $320 to $280.

Citigroup Maintains Neutral on Lithia Motors, Lowers Price Target to $280

Citigroup analyst David Lebovitz maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Neutral and lowers the price target from $94 to $91.

BMRN

Citigroup Maintains Neutral on Biomarin Pharmaceutical, Lowers Price Target to $91

Citigroup analyst Michelle Fang maintains New Oriental Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) with a Buy and raises the price target from $66 to $127.

New Oriental Education & Technology Group

Citigroup Maintains Buy on New Oriental Education, Raises Price Target to $127

Citigroup analyst Andrew Kaplowitz maintains Fortive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) with a Buy and lowers the price target from $101 to $98.

Citigroup Maintains Buy on Fortive, Lowers Price Target to $98

Microsoft Sees FY24 Productivity And Business Processes Revenue $19.9B-$20.2B; Intelligent Cloud Revenue $28.4B-$28.7B; More Personal Computing Revenue $15.2B-$15.6B; Cost Of Revenue COGS Of $19.6B-$19.8B; Operating Expenses Of $17.15B-$17.25B; Effective Tax Rate ~18%

Guidance

MSFT

Microsoft Sees FY24 Productivity And Business Processes Revenue $19.9B-$20.2B; Intelligent Cloud Revenue $28.4B-$28.7B; More Personal Computing Revenue $15.2B-$15.6B; Cost Of Revenue COGS Of $19.6B-$19.8B; Operating Expenses Of $17.15B-$17.25B; Effective Tax Rate ~18%

Citigroup analyst Anthony Pettinari maintains Packaging Corp of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>) with a Neutral and lowers the price target from $183 to $181.

Citigroup Maintains Neutral on Packaging Corp of America, Lowers Price Target to $181

Citigroup analyst Christopher Allen maintains Virtu Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRT#NASDAQ">VIRT</a>) with a Buy and raises the price target from $22.5 to $24.5.

VIRT

Citigroup Maintains Buy on Virtu Finl, Raises Price Target to $24.5

Citigroup analyst Thomas Palmer maintains Bunge Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>) with a Buy and raises the price target from $117 to $122.

Citigroup Maintains Buy on Bunge Global, Raises Price Target to $122

Citigroup analyst Fatima Boolani maintains Fastly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) with a Neutral and lowers the price target from $20 to $15.

FSLY

Citigroup Maintains Neutral on Fastly, Lowers Price Target to $15

Citigroup analyst Fatima Boolani maintains Akamai Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAM#NASDAQ">AKAM</a>) with a Neutral and lowers the price target from $140 to $117.

AKAM

Citigroup Maintains Neutral on Akamai Techs, Lowers Price Target to $117

Citigroup analyst Joanne Wuensch maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Buy and raises the price target from $79 to $85.

Citigroup Maintains Buy on Boston Scientific, Raises Price Target to $85

Citigroup analyst Patrick Cunningham maintains Sherwin-Williams (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) with a Buy and lowers the price target from $390 to $370.

Citigroup Maintains Buy on Sherwin-Williams, Lowers Price Target to $370

Citigroup analyst Jon Tower maintains Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) with a Buy and raises the price target from $3358 to $3369.

Citigroup Maintains Buy on Chipotle Mexican Grill, Raises Price Target to $3369

Citigroup analyst Jason Gursky maintains Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) with a Buy and lowers the price target from $252 to $224.

Citigroup Maintains Buy on Boeing, Lowers Price Target to $224

Citigroup analyst Andrew Kaplowitz maintains GE Aero (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) with a Buy and raises the price target from $120.43 to $186.

Citigroup Maintains Buy on GE Aero, Raises Price Target to $186

Citigroup analyst Jason Gursky maintains General Dynamics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>) with a Buy and raises the price target from $300 to $320.

Citigroup Maintains Buy on General Dynamics, Raises Price Target to $320

Citigroup analyst Andrew Kaplowitz maintains Vertiv Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) with a Buy and raises the price target from $102 to $110.

Citigroup Maintains Buy on Vertiv Hldgs, Raises Price Target to $110

Citigroup analyst Atif Malik maintains Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) with a Buy and raises the price target from $975 to $1025.

LRCX

Citigroup Maintains Buy on Lam Research, Raises Price Target to $1025

It's JPM time! Which medtechs are expected to issue updates this week?

Personalis and ClearNote Health enter into a partnership

Personalis GAAP EPS of -$0.54 misses by $0.04, revenue of $19.7M beats by $0.39M

Personalis, Inc. (PSNL) Q4 2023 Earnings Call Transcript

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on RxSight (RXST – Research Report) and Personalis (PSN...

Analysts Are Bullish on Top Healthcare Stocks: RxSight (RXST), Personalis (PSNL)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sensei Biotherapeutics (SNSE – Research Report), Abb...

Analysts Offer Insights on Healthcare Companies: Sensei Biotherapeutics (SNSE), Abbott Labs (ABT) and Personalis (PSNL)

In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on Personalis (PSNL – Research Report), with a price target of $4.00...

Buy Rating Affirmed for Personalis Amidst Strategic Partnerships and Revenue Growth Prospects

TD Cowen analyst Daniel Brennan has maintained their bullish stance on PSNL stock, giving a Buy rating on February 29. Daniel Brennan has given his...

Buy Rating Affirmed: Personalis's Strategic Advances and Financial Health Signal Promising Growth in 2024

XTIA, PSNL and LIDR among mid-day movers

Analyst Michael Matson of Needham maintained a Buy rating on Personalis (PSNL – Research Report), retaining the price target of $3.50. Michael Mats...

Buy Rating Affirmed for Personalis, Inc. on Strong Growth Prospects and Innovative Cancer Assays

AISP

AKYA

ANGH

ANVS

APAC

AQST

ATEC

ATRC

AXNX

CSTL

EXAS

HOLX

ILMN

INGN

INLX

INMD

KIDS

LFCR

LIDR

LUCD

MASI

NSTG

NTRA

PACB

QTRX

RETO

RLMD

RXST

SGHT

SIBN

SLGC

SNSE

STAA

TRUG

TSHA

WULF

XRAY

XTIA

XTLB

Press Releases

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology

Personalis to Participate at Upcoming Investor Conferences

Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results

Personalis Reports Fourth Quarter and Full Year 2023 Financial Results

Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring

Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting